HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin.

Abstract
New antibodies against a U3 snRNP, which were named anti-Myo 22/25 antibodies, were detected in four (8%) of 53 serum samples from patients with polymyositis/dermatomyositis (PM/DM) by RNA immunoprecipitation. In the protein immunoprecipitation analysis, all four serum samples precipitated 22 kDa and 25 kDa proteins, which were not precipitated by normal serum or serum positive for antifibrillarin antibodies. Three of the four PM/DM patients had other identified autoantibodies including anti-PL-12 antibodies, antihistone antibodies (AHA), anti-SS-A antibodies and anti-SS-B antibodies defined by double immunodiffusion, ELISA or RNA immunoprecipitation, although there were no significant correlations between anti-Myo 22/25 antibodies and clinical or laboratory findings. There may be a subgroup of PM/DM patients whose sera are positive for anti-Myo 22/25 antibodies.
AuthorsM Kubo, H Ihn, M Kuwana, K Yamane, N Yazawa, K Tamaki
JournalClinical and experimental immunology (Clin Exp Immunol) Vol. 126 Issue 2 Pg. 339-44 (Nov 2001) ISSN: 0009-9104 [Print] England
PMID11703380 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • Chromosomal Proteins, Non-Histone
  • Macromolecular Substances
  • Ribonucleoproteins, Small Nucleolar
  • fibrillarin
  • ribonucleoprotein, U3 small nucleolar
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibody Specificity
  • Autoantibodies (blood)
  • Chromosomal Proteins, Non-Histone (chemistry, immunology, isolation & purification)
  • Dermatomyositis (immunology)
  • Female
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Macromolecular Substances
  • Male
  • Middle Aged
  • Molecular Weight
  • Polymyositis (immunology)
  • Precipitin Tests
  • Ribonucleoproteins, Small Nucleolar (chemistry, immunology, isolation & purification)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: